Current News
PRESS RELEASE
Accera, Inc. Sponsors Alzheimer’s Association’s 2009 ICAD Conference
Broomfield, CO, February 19th, 2009 – Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system (CNS) diseases, announced today it is a SILVER level sponsor of the 2009 International Conference on Alzheimer’s Disease (ICAD). The annual conference, put on by the Alzheimer’s Association, is the world’s leading forum on dementia research. ICAD 2009 will take place July 11-16 in Vienna, Austria.
“Alzheimer’s is a progressive and fatal disease that significantly impacts millions of patients, their families and caregivers,” said Steve Orndorff, Ph.D., Accera’s founder and CEO. “As a company focused on CNS disorders, Accera is committed to improving the care and quality of life of Alzheimer’s patients who are in need of innovative, safe, new therapeutic options. By supporting ICAD we are joining the Alzheimer’s Association in their quest to advance research, care and support for AD.”
In the U.S., 5.2 million people are living with AD and it has become the sixth leading cause of death. There is currently no cure for AD and there is a tremendous need for new and innovative therapies.
ICAD 2009 is expected to draw approximately 5,000
researchers, clinicians and neurologists from around
the world to engage in a multidisciplinary exchange
of ideas. The international sharing of research
looks to advance prevention methods, treatments
and a cure for AD.
About ICAD
The Alzheimer’s Association International Conference
on Alzheimer's Disease (ICAD) is the largest gathering
of international leaders in Alzheimer research
and care. At ICAD, researchers from around the
world share groundbreaking information and resources
on the cause, diagnosis, treatment and prevention
of Alzheimer’s and related disorders. As a part
of the Association’s research program, ICAD serves
as a catalyst for generating new knowledge about
dementia and fostering a vital, collegial research
community.
About the Alzheimer’s Association
The Alzheimer’s Association, the nonprofit world
leader in Alzheimer’s research and support, is
the first and largest U.S. voluntary health organization
dedicated to finding prevention methods, treatments
and an eventual cure for Alzheimer’s. For more
than 25 years, the donor-supported Alzheimer’s
Association has provided reliable information and
care consultation; created supportive services
for families; increased funding for dementia research;
and influenced public policy changes. For more
information, call (800) 272-3900 or visit www.alz.org.
About Accera, Inc.
Accera, Inc., a privately held biotechnology company,
discovers and develops product breakthroughs in
treating central nervous system disorders. Accera’s
novel therapeutic approaches positively impact
patients with neurodegenerative disorders, who
are in need of effective, well-tolerated treatments.
Through its proprietary scientific platform, Accera
is developing therapies that address metabolic
deficiencies by providing an alternative energy
source to the brain.
###